Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 22.09
NVO's Cash to Debt is ranked higher than
69% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. NVO: 22.09 )
NVO' s 10-Year Cash to Debt Range
Min: 0.29   Max: 67.3
Current: 22.09

0.29
67.3
Equity to Asset 0.52
NVO's Equity to Asset is ranked higher than
63% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVO: 0.52 )
NVO' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.73
Current: 0.52

0.52
0.73
Interest Coverage 884.41
NVO's Interest Coverage is ranked higher than
53% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 884.41 )
NVO' s 10-Year Interest Coverage Range
Min: 5.69   Max: 884.41
Current: 884.41

5.69
884.41
F-Score: 6
Z-Score: 20.57
M-Score: -2.66
WACC vs ROIC
12.32%
97.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.84
NVO's Operating margin (%) is ranked higher than
98% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. NVO: 38.84 )
NVO' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 38.84
Current: 38.84

10.5
38.84
Net-margin (%) 29.82
NVO's Net-margin (%) is ranked higher than
96% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. NVO: 29.82 )
NVO' s 10-Year Net-margin (%) Range
Min: 11.39   Max: 30.13
Current: 29.82

11.39
30.13
ROE (%) 69.30
NVO's ROE (%) is ranked higher than
99% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. NVO: 69.30 )
NVO' s 10-Year ROE (%) Range
Min: 11.85   Max: 63.92
Current: 69.3

11.85
63.92
ROA (%) 38.31
NVO's ROA (%) is ranked higher than
99% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. NVO: 38.31 )
NVO' s 10-Year ROA (%) Range
Min: 8.5   Max: 37.03
Current: 38.31

8.5
37.03
ROC (Joel Greenblatt) (%) 139.78
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. NVO: 139.78 )
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 141.95
Current: 139.78

6.89
141.95
Revenue Growth (3Y)(%) 13.20
NVO's Revenue Growth (3Y)(%) is ranked higher than
84% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. NVO: 13.20 )
NVO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.3   Max: 23
Current: 13.2

0.3
23
EBITDA Growth (3Y)(%) 16.70
NVO's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NVO: 16.70 )
NVO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 8.4   Max: 25.7
Current: 16.7

8.4
25.7
EPS Growth (3Y)(%) 18.80
NVO's EPS Growth (3Y)(%) is ranked higher than
88% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NVO: 18.80 )
NVO' s 10-Year EPS Growth (3Y)(%) Range
Min: 10.3   Max: 29.7
Current: 18.8

10.3
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVO Guru Trades in Q1 2014

Ken Fisher 13,631,979 sh (+0.58%)
Jim Simons 16,079,800 sh (-1.46%)
Tom Gayner 1,075,000 sh (-2.80%)
Mario Gabelli 7,665 sh (-10.04%)
Ruane Cunniff 242,630 sh (-21.98%)
Steven Cohen 9,962 sh (-36.57%)
Murray Stahl 7,740 sh (-80.00%)
» More
Q2 2014

NVO Guru Trades in Q2 2014

Jim Simons 16,953,000 sh (+5.43%)
Ken Fisher 13,741,529 sh (+0.80%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli 7,620 sh (-0.59%)
Ruane Cunniff 160,492 sh (-33.85%)
» More
Q3 2014

NVO Guru Trades in Q3 2014

Tom Gayner 1,075,000 sh (unchged)
Murray Stahl 7,740 sh (unchged)
Ken Fisher 13,385,913 sh (-2.59%)
Jim Simons 16,106,100 sh (-5.00%)
Mario Gabelli 6,720 sh (-11.81%)
Ruane Cunniff 75,642 sh (-52.87%)
» More
Q4 2014

NVO Guru Trades in Q4 2014

Steven Cohen 481,700 sh (New)
Ruane Cunniff 82,192 sh (+8.66%)
Murray Stahl 7,907 sh (+2.16%)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli 6,720 sh (unchged)
Ken Fisher 13,039,648 sh (-2.59%)
Jim Simons 15,614,600 sh (-3.05%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.30
NVO's P/E(ttm) is ranked higher than
92% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 38.30 )
NVO' s 10-Year P/E(ttm) Range
Min: 12.11   Max: 39.08
Current: 38.3

12.11
39.08
Forward P/E 25.91
NVO's Forward P/E is ranked higher than
89% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 25.91 )
N/A
PE(NRI) 38.70
NVO's PE(NRI) is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 38.70 )
NVO' s 10-Year PE(NRI) Range
Min: 12.09   Max: 39.1
Current: 38.7

12.09
39.1
P/B 25.50
NVO's P/B is ranked lower than
61% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. NVO: 25.50 )
NVO' s 10-Year P/B Range
Min: 3.5   Max: 25.86
Current: 25.5

3.5
25.86
P/S 11.35
NVO's P/S is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. NVO: 11.35 )
NVO' s 10-Year P/S Range
Min: 2.81   Max: 11.64
Current: 11.35

2.81
11.64
PFCF 37.00
NVO's PFCF is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 37.00 )
NVO' s 10-Year PFCF Range
Min: 12.1   Max: 47.01
Current: 37

12.1
47.01
POCF 32.31
NVO's POCF is ranked higher than
94% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 32.31 )
NVO' s 10-Year POCF Range
Min: 7.96   Max: 32.61
Current: 32.31

7.96
32.61
EV-to-EBIT 28.14
NVO's EV-to-EBIT is ranked higher than
95% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 28.14 )
NVO' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 29.3
Current: 28.14

9.1
29.3
PEG 1.97
NVO's PEG is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 1.97 )
NVO' s 10-Year PEG Range
Min: 0.54   Max: 1.87
Current: 1.97

0.54
1.87
Shiller P/E 54.30
NVO's Shiller P/E is ranked higher than
95% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 54.30 )
NVO' s 10-Year Shiller P/E Range
Min: 18.94   Max: 55.01
Current: 54.3

18.94
55.01
Current Ratio 1.37
NVO's Current Ratio is ranked higher than
54% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. NVO: 1.37 )
NVO' s 10-Year Current Ratio Range
Min: 1.37   Max: 2.45
Current: 1.37

1.37
2.45
Quick Ratio 1.04
NVO's Quick Ratio is ranked higher than
53% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NVO: 1.04 )
NVO' s 10-Year Quick Ratio Range
Min: 1.04   Max: 1.91
Current: 1.04

1.04
1.91
Days Inventory 266.65
NVO's Days Inventory is ranked higher than
79% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 266.65 )
NVO' s 10-Year Days Inventory Range
Min: 201.98   Max: 417.53
Current: 266.65

201.98
417.53
Days Sales Outstanding 53.60
NVO's Days Sales Outstanding is ranked higher than
86% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. NVO: 53.60 )
NVO' s 10-Year Days Sales Outstanding Range
Min: 45.09   Max: 152.61
Current: 53.6

45.09
152.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.33
NVO's Dividend Yield is ranked higher than
64% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 1.04 vs. NVO: 1.33 )
NVO' s 10-Year Dividend Yield Range
Min: 0.79   Max: 2.47
Current: 1.33

0.79
2.47
Dividend Payout 0.45
NVO's Dividend Payout is ranked higher than
95% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 0.45 )
NVO' s 10-Year Dividend Payout Range
Min: 0.13   Max: 0.45
Current: 0.45

0.13
0.45
Dividend growth (3y) 46.20
NVO's Dividend growth (3y) is ranked higher than
97% of the 124 Companies
in the Global Biotechnology industry.

( Industry Median: 11.10 vs. NVO: 46.20 )
NVO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 49.4
Current: 46.2

0
49.4
Yield on cost (5-Year) 6.16
NVO's Yield on cost (5-Year) is ranked higher than
93% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. NVO: 6.16 )
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 3.74   Max: 11.7
Current: 6.16

3.74
11.7
Share Buyback Rate 2.60
NVO's Share Buyback Rate is ranked higher than
97% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -9.60 vs. NVO: 2.60 )
NVO' s 10-Year Share Buyback Rate Range
Min: 3   Max: 0.4
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 26.50
NVO's Price/Tangible Book is ranked lower than
60% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. NVO: 26.50 )
NVO' s 10-Year Price/Tangible Book Range
Min: 3.15   Max: 17.72
Current: 26.5

3.15
17.72
Price/DCF (Projected) 4.70
NVO's Price/DCF (Projected) is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 4.70 )
NVO' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 3.18
Current: 4.7

1.3
3.18
Price/Median PS Value 2.30
NVO's Price/Median PS Value is ranked higher than
70% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. NVO: 2.30 )
NVO' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.57
Current: 2.3

0.6
1.57
Price/Peter Lynch Fair Value 1.90
NVO's Price/Peter Lynch Fair Value is ranked higher than
98% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 1.90 )
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.24
Current: 1.9

0.07
1.24
Price/Graham Number 6.80
NVO's Price/Graham Number is ranked higher than
90% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 6.80 )
NVO' s 10-Year Price/Graham Number Range
Min: 1.56   Max: 4.53
Current: 6.8

1.56
4.53
Earnings Yield (Greenblatt) 3.60
NVO's Earnings Yield (Greenblatt) is ranked higher than
93% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. NVO: 3.60 )
NVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 11
Current: 3.6

3.4
11
Forward Rate of Return (Yacktman) 22.78
NVO's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 15.60 vs. NVO: 22.78 )
NVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 36.1
Current: 22.78

1.7
36.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:0QIU.UK, NOVO B.Denmark, NONOF.USA, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
Additional Changes to the Nintai Portfolio Apr 08 2015 
Probability and Magnitude in Investing Apr 02 2015 
Nintai Returns: Q1 2015 Apr 01 2015 
These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 


More From Other Websites
Business Highlights Apr 17 2015
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog Apr 13 2015
Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog Apr 09 2015
FDA accepts Novo Nordisk's resubmitted application for insulin drug Apr 07 2015
Hedge Funds Made A Bundle By Betting On Amazon.com, Inc. (AMZN), Apple, and Pfizer Inc Apr 01 2015
FDA Urged to Fine Drugmakers Over Ads Apr 01 2015
Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 March 2015) Apr 01 2015
Top First Quarter European ETFs Mar 31 2015
The Best and Worst Medalists of 2015's First Quarter Mar 30 2015
Novo Nordisk’s Insulin Move Is Right Medicine Mar 29 2015
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among Billionaire Jim Simons’... Mar 27 2015
Novo Nordisk to Submit Interim DEVOTE Data to the FDA - Analyst Blog Mar 27 2015
Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog Mar 27 2015
Can The Uptrend Continue for Novo Nordisk (NVO)? - Tale of the Tape Mar 27 2015
March 27 Premarket Briefing: 10 Things You Should Know Mar 27 2015
Cruise news you can use, plus more Friday business headlines Mar 27 2015
Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog Mar 26 2015
Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog Mar 26 2015
Red Hat, Signet Top Buy Points En Route To New Highs Mar 26 2015
Novo Nordisk (NVO) Stock Gains Today on Drug Application Resubmission Mar 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK